History of Tropical Medicine

In British India, military and East India Company practitioners developed what they often called “tropical hygiene” before a metropolitan specialty existed. Their work included environmental observation, sanitation, diet, materia medica, and exchanges—unequal but real—with South Asian practitioners. Mark Harrison's study of Tropical Medicine in Nineteenth-Century India cautions against the later “pioneer” story in which scientific knowledge simply travelled from European centres to passive colonies.

Cinchona bark makes the same point, but its origin story remains uncertain. Bark from Andean Cinchona species entered European fever treatment through seventeenth-century encounters among Indigenous communities, Jesuits, merchants, and patients. Pierre-Joseph Pelletier and Joseph Bienaimé Caventou isolated quinine in Paris in 1820; nineteenth-century colonial governments then moved cinchona into Asian plantation systems; the Royal Botanic Gardens, Kew documents its own role in transferring plants to India between 1850 and 1865. A review of the surviving records by Louis H. Miller and colleagues finds no primary evidence sufficient to identify a lone “discoverer” or to establish exactly how earlier Andean uses related to malaria as later defined.

The word “tropical” therefore named more than latitude. Malaria had existed in Europe and North America, while many illnesses concentrated in warmer regions because vectors, rainfall, housing, work, land use, nutrition, mobility, and access to care interacted. The category made diverse places appear medically alike and especially dangerous to Europeans. It could obscure the political economy that helped distribute disease.

In 1877 Patrick Manson, working in Xiamen (then commonly rendered “Amoy” in English), showed that mosquitoes took up filarial worms from blood and were part of the parasite's development. In 1880 the French army physician Alphonse Laveran observed pigmented protozoan parasites in the blood of patients at Constantine, Algeria. Manson later urged Ronald Ross, an Indian Medical Service officer, to test a mosquito hypothesis for malaria.

At Secunderabad on 20 August 1897, Ross found developing parasites in a mosquito fed on a patient with malaria. In 1898 he reconstructed the mosquito phase more fully with a malaria parasite of birds. That was not yet an experimental demonstration of human transmission. In Italy later in 1898, Giovanni Battista Grassi identified the relevant Anopheles mosquitoes, and Amico Bignami and Giuseppe Bastianelli demonstrated human malaria transmission through their bites. Ross and Grassi then fought a bitter priority dispute; Ross alone received the 1902 Nobel Prize. Francis E. G. Cox's historical reconstruction of the parasite and vector discoveries supports a distributed account: Laveran, Manson, Ross, the Italian malariologists, experimental subjects, laboratory workers, and animal models supplied different indispensable parts.

Yellow fever produced another contested sequence. The Cuban physician Carlos J. Finlay publicly proposed mosquito transmission in Havana in 1881 and supplied ideas, publications, and mosquito material to the U.S. Army Yellow Fever Commission. In 1900 Walter Reed, James Carroll, Aristides Agramonte, and Jesse Lazear used controlled exposures in Cuba to distinguish mosquito transmission from contaminated bedding and other proposed routes. Their results helped make mosquito control practicable, but “Walter Reed discovered yellow fever transmission” erases Finlay, Agramonte, Carroll, Lazear, Cuban clinical settings, and the volunteers.

Those experiments also require ethical context. Some volunteers signed contracts and received payment, an unusual attempt to state risk at the time, but the studies deliberately exposed people to a potentially fatal infection and took place decades before independent ethical review became standard. Euzebiusz Jamrozik and Michael J. Selgelid's history of human challenge studies places these contracts and payments in their period without equating them with modern protections. The commission's 1900 Etiology of Yellow Fever: A Preliminary Note is a primary report written to announce its bacteriological and experimental findings. It documents what the investigators did and claimed; it cannot by itself settle priority, represent every participant's experience, or make the research equivalent to present-day consent standards.

Parasite and vector research suggested material interventions: screens and bed nets, drainage, safer water storage, clearing breeding sites, protecting ill people from mosquitoes, insecticides, case detection, and drug treatment. The history of malaria shows that laboratory and ecological approaches could reinforce one another. Yet campaigns were shaped by budgets and political priorities. Protecting barracks, settler quarters, ports, plantations, mines, or canal works was not the same project as building broadly accessible health services.

Sleeping sickness—human African trypanosomiasis—became a defining test of the specialty during severe epidemics in East and Central Africa after 1900. Scientists investigated trypanosomes, tsetse flies, animal reservoirs, and arsenical drugs. Colonial governments also imposed cordons, medical passes, compulsory examinations, isolation camps, bush clearing, game destruction, and forced resettlement. Atoxyl sometimes suppressed infection but could cause severe toxicity, including blindness. Policies differed by territory and changed over time; there was no single colonial programme.

Daniel Headrick's comparative history documents both the epidemic emergency and the limited, dangerous methods available. Jonathan Jackson's study of 1939–1945 Ulanga, Tanganyika goes further: officials used the threat of sleeping sickness to justify “concentrations,” their own historical term for compulsory compact settlements, while pursuing agricultural and political reorganisation. Residents resisted and fled. The case warns against reading administrative reports as transparent measures of either consent or success.

Disease-specific campaigns could reduce transmission while also imposing injury, disrupted livelihoods, or mistrust. Their outcomes must therefore be judged on at least two levels: epidemiological effects and the conditions under which people were examined, treated, moved, or excluded. “Beneficial” and “coercive” are not mutually exclusive descriptions of the same campaign.

Independence expanded the authority of national ministries, universities, and research institutes in Asia, Africa, the Caribbean, and the Pacific. International agencies and philanthropic funders also became more important. “International health,” “development medicine,” and later “global health” overlapped with tropical medicine but were not simple new names for it. Roberta Bivins's study of postwar Britain shows a slower institutional transformation: research objects, funding networks, and ideas about race could persist even as colonial language was revised.

WHO's Global Malaria Eradication Programme, launched in 1955, joined indoor residual spraying, drug treatment, and surveillance in a time-limited campaign. It achieved elimination in some countries but never fully included most of Sub-Saharan Africa; resistance, logistics, and weak general health services constrained it. In 1969 WHO redirected policy toward control. WHO's technical review of malaria control, elimination, and eradication records why the programme was never as global as its name implied. This was not proof that vector control “failed,” but it did expose the limits of treating a technically effective tool as a complete health system.

Tu Youyou and artemisinin offer a different postwar geography of research. Project 523 began in China in 1967 during the Vietnam War and the Cultural Revolution, involving hundreds of researchers across dozens of institutions. Tu's team consulted written and living Chinese medical traditions; her later account identifies a fourth-century recipe associated with Ge Hong as the clue to avoiding high-temperature extraction. Tu's and other teams purified the compound, determined its structure, tested it, and developed derivatives. Artemisinin was therefore neither an unchanged ancient remedy nor one person's isolated invention: it emerged from textual knowledge, state mobilisation, laboratory extraction, clinical work, and collective pharmaceutical development. Zongru Guo's history of China's artemisinin research reconstructs that multi-institutional sequence.

TDR's creation in 1974 signalled a further shift toward research and training in disease-endemic countries. Unequal funding, authorship, laboratory capacity, data ownership, and agenda-setting nevertheless remain part of the field's history. A critical account can recognise the value of parasitology, therapeutics, and vector control while still asking who defined the problem, bore the risk, received the resources, and controlled the evidence.